Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina
November 30, 2021
The partnership will focus on the licensing, supply, and expected commercialization of Avicanna’s cannabinoid-based drug candidate Trunerox™, in Argentina in the second half 2022 TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the... Read more
Avicanna Executes Multi Year Agreement to Supply Brazilian Pharmaceutical Company with THC and CBD Cannabis Extracts
July 7, 2021
Ryan Allway July 7th, 2021 Avicanna’s standardized CBD and THC Cannabis Extracts are to be utilized to produce a range of cannabis-derived products for the Brazilian market of 211 million people. Fulfillment of purchase orders based on preliminary forecasts for 2022 is expected to generate approximately CAD$4 million in... Read more
